In this study, we investigate whether p-eIF2α could serve as a prognostic biomarker in breast cancer, with a particular focus on differences between different molecular subtypes; and provide evidence for a new therapeutic target in breast cancer. The gene discussed is EIF2A; the disease is breast carcinoma.